# US 2025/0026811 A1 · Compositions and Methods for the Delivery of Therapeutic Biologics for Treatment of Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0026811 A1
- Document ID: US20250026811A1
- Status: Published application
- Kind: A1
- Application number: 18/906,489
- Filed: 2024-10-04
- Published: 2025-01-23
- Earliest claimed: 2019-09-13
- Assignees: Elektrofi, Inc.
- Applicants: Elektrofi, Inc.
- Inventors: Paul Brown; Tyler L. Carter; Lyndon Fitzgerald Charles, JR.; Chase Spenser Coffman; Daniel Benjamin Dadon; Lisa Liu; Sadiqua Shadbar; Chaitanya Sudrik; Yi Tang; Shankul Vartak
- Web page: https://patentgrep.com/patent/US20250026811A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 9/10: Dispersions; Emulsions
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compositions and methods for treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising a plurality of particles comprising at least one therapeutic biologic suspended in a pharmaceutically acceptable liquid carrier.

## Claims

### Claim 1

A composition comprising particles, wherein a plurality of the particles comprise greater than 65% of a therapeutic agent by weight; and wherein the composition is co-formulated with a hyaluronan degrading agent.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the therapeutic agent is a therapeutic biologic or salt thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the hyaluronan degrading agent is a hyaluronidase enzyme.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition co-formulated with a hyaluronan degrading agent includes a water content of less than about 7% by weight.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the water content is less than about 2% by weight.

### Claim 6 (depends on 1)

The composition of claim 1, further comprising a stabilizer.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the stabilizer comprises a salt, a carbohydrate, a saccharide, an amino acid, or a combination thereof.

### Claim 8 (depends on 6)

The composition of claim 6, wherein the stabilizer is a sugar, an amino acid, or a protein.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the particles are suspended in a carrier.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the carrier comprises ethyl oleate or propylene glycol diesters.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the therapeutic agent is an antibody or a fragment thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein a plurality of particles have less than about 25% internal void space.

### Claim 13 (depends on 1)

The composition of claim 1, wherein a plurality of the particles have less than about 10% aggregation of the therapeutic biologic or salt thereof.

### Claim 14 (depends on 1)

The composition of claim 1, wherein a plurality of the particles have a circularity from about 0.80 to about 1.00.

### Claim 15 (depends on 1)

The composition of claim 1, wherein a plurality of the particles have less than about 7% residual moisture by weight.

### Claim 16 (depends on 1)

The composition of claim 1, wherein a plurality of the particles comprise greater than about 70% therapeutic biologic or salt thereof by weight.

### Claim 17 (depends on 1)

The composition of claim 1, wherein a plurality of the particles have less than about 50% change in charge variants of the therapeutic biologic or salt thereof.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the concentration of the therapeutic biologic or salt thereof in the composition is from about 20 mg/mL to about 700 mg/mL.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the composition has a viscosity of less than about 200 mPa·s.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the composition is free of insoluble Subvisible Particles (SvPs) upon dissolution in water.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the therapeutic biologic or salt thereof in the composition is stable for at least three months.

### Claim 22

A composition comprising particles, wherein:
a plurality of the particles comprise greater than 65% of a therapeutic biologic or salt thereof by weight, and further comprise a surfactant, an amino acid, or a combination thereof;
the particles are suspended in a non-aqueous carrier; and
the concentration of the therapeutic biologic or salt thereof in the composition is from about 20 mg/mL to about 700 mg/mL, and
wherein the composition is co-formulated with a hyaluronan degrading agent.
